Trial
NCT01902381
CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
National Cancer Institute (NCI)
Condition
Previously Treated Myelodysplastic Syndromes
Intervention
6,8-bis(benzylthio)octanoic acid
Why stopped
Drug sponsor suspended study prematurely then study was terminated. Expected enrollment was not met.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-17